Physician profile
Umber Dube
NPI 1003484346
$1,858.59
in general payments reported to CMS, 2019-2025
14 companies · $727 in 2025
The $727 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $543 · 2024: $589 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,760 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.59 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $259.31 | 2023 | Opzelura |
| Ucb, INC. | $228.56 | 2024-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.02 | 2025 | Spevigo |
| Dermavant Sciences, INC. | $154.99 | 2023 | Vtama |
| Galderma Laboratories, L.P. | $144.46 | 2025 | Nemluvio |
| Janssen Scientific Affairs, LLC | $138.37 | 2024 | Tremfya |
| Regeneron Pharmaceuticals, INC. | $129.86 | 2024 | Libtayo |
| Arcutis Biotherapeutics, INC. | $128.79 | 2023 | |
| Genzyme Corporation | $122.08 | 2024 | |
| Novartis Pharmaceuticals Corporation | $114.11 | 2024 | |
| Eli Lilly and Company | $99.00 | 2025 | |
| Lilly USA, LLC | $83.24 | 2025 | Ebglyss, Taltz |
| Pfizer INC. | $56.49 | 2025 | |
| Janssen Biotech, INC. | $23.31 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umber Dube listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.